GW Henssler & Associates Ltd. Sells 48 Shares of Vertex Pharmaceuticals Incorporated $VRTX

GW Henssler & Associates Ltd. lessened its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 22,763 shares of the pharmaceutical company’s stock after selling 48 shares during the period. GW Henssler & Associates Ltd.’s holdings in Vertex Pharmaceuticals were worth $10,134,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of VRTX. Activest Wealth Management bought a new stake in Vertex Pharmaceuticals during the first quarter valued at about $25,000. Clal Insurance Enterprises Holdings Ltd grew its holdings in Vertex Pharmaceuticals by 450.0% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 45 shares during the period. Flaharty Asset Management LLC bought a new stake in Vertex Pharmaceuticals during the first quarter valued at about $32,000. American National Bank & Trust grew its holdings in Vertex Pharmaceuticals by 515.4% during the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock valued at $36,000 after purchasing an additional 67 shares during the period. Finally, University of Texas Texas AM Investment Management Co. bought a new stake in Vertex Pharmaceuticals during the first quarter valued at about $46,000. Institutional investors own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs acquired 5,000 shares of the firm’s stock in a transaction on Wednesday, August 6th. The shares were acquired at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the transaction, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. This trade represents a 12.50% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Trading Down 1.7%

Shares of Vertex Pharmaceuticals stock opened at $407.79 on Friday. The stock has a 50 day moving average of $393.91 and a 200 day moving average of $439.18. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The firm has a market cap of $104.55 billion, a PE ratio of 29.15 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. During the same period in the prior year, the company earned ($12.83) earnings per share. The firm’s revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Leerink Partners raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and dropped their price objective for the stock from $458.00 to $456.00 in a research note on Thursday, September 25th. Truist Financial set a $490.00 price objective on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 5th. UBS Group set a $553.00 price objective on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Canaccord Genuity Group dropped their price objective on Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating for the company in a research note on Wednesday, August 6th. Finally, Royal Bank Of Canada dropped their price objective on Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating for the company in a research note on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $494.38.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.